This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
The prognosis of glioblastoma patients has not improved over the last decades, as the median survival time is still in the range of 12 months after diagnosis.1 Long-term survival, defined as a survival time of ≥3 years after diagnosis,2 is exceedingly rare. However, a small percentage of glioblastoma patients, in particular those with a favorable constellation of prognostic factors, may experience a survival time of several years.2,3⇓ We report a patient with a recurrent glioblastoma now free of disease for 7 years after reoperation and treatment by somatic gene therapy.
Case report.
In 1995, we diagnosed a right frontoparietal tumor in a 37-year-old man (see the supplementary material on the Neurology Web site; go to www.neurology.org). After tumor resection, a glioblastoma multiforme World Health Organization grade IV was diagnosed (see the supplementary material on the Neurology Web site). Postoperatively, standard external beam radiation with a cumulative dose of 60.3 Gy was delivered. In 1996, a control MR scan showed a tumor recurrence at the wall of the …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Topics Discussed
Alert Me
Recommended articles
Challenges in the design and conduct of phase III brain tumor therapy trials
The prognostic impact of prior low grade histology in patients with anaplastic gliomas
Invited Article: The expanding impact of molecular biology on the diagnosis and treatment of gliomas
Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma